Results 1 to 10 of about 6,916,201 (263)

Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture [PDF]

Bioactive Materials
Patient-derived tumor organoids (PDTOs) shows great potential as a preclinical model. However, the current methods for establishing PDTOs primarily focus on modulating local properties, such as sub-micrometer topographies.
Jiaxin Wang, Zhilin Sui, Wei Huang, Zhentao Yu, Ling Guo   +4 more
doaj   +6 more sources

Patient‐ and xenograft‐derived organoids recapitulate pediatric brain tumor features and patient treatments [PDF]

EMBO Molecular Medicine, 2023
Brain tumors are the leading cause of cancer‐related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and hard to establish.
Chiara Lago, Aniello Federico, Gloria Leva, Norman L Mack, Benjamin Schwalm, Claudio Ballabio, Matteo Gianesello, Luana Abballe, Isabella Giovannoni, Sofia Reddel, Sabrina Rossi, Nicolas Leone, Andrea Carai, Angela Mastronuzzi, Alessandra Bisio, Alessia Soldano, Concetta Quintarelli, Franco Locatelli, Marcel Kool, Evelina Miele, Luca Tiberi   +20 more
doaj   +4 more sources

Assessing tumor heterogeneity and FLOT/FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids [PDF]

International Journal of Immunopathology and Pharmacology
Background Gastric cancer is a deadly disease with poor prognosis and unfavorable therapeutic outcomes. It is known that a major cause of treatment failure for gastric cancer is related to tumor heterogeneity.
Chih-Cheng Cheng, Bor-Chyuan Su, Wei-Yu Chen, Hsin-Hsien Yu   +3 more
doaj   +3 more sources

Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids. [PDF]

Int J Mol Sci, 2021
Differential chemo-sensitivity of cancer cells, which is attributed to the cellular heterogeneity and phenotypic variation of cancer cells, is considered to be the main reason for tumor recurrence after chemotherapy.
Choi SY, Cho YH, Kim DS, Ji W, Choi CM, Lee JC, Rho JK, Jeong GS.   +7 more
europepmc   +4 more sources

Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. [PDF]

Int J Mol Sci, 2022
An obstacle to effective uniform treatment of glioblastoma, especially at recurrence, is genetic and cellular intertumoral heterogeneity. Hence, personalized strategies are necessary, as are means to stratify potential targeted therapies in a clinically relevant timeframe.
Ratliff M, Kim H, Qi H, Kim M, Ku B, Azorin DD, Hausmann D, Khajuria RK, Patel A, Maier E, Cousin L, Ogier A, Sahm F, Etminan N, Bunse L, Winkler F, El-Khoury V, Platten M, Kwon YJ.   +18 more
europepmc   +4 more sources

Patient-derived tumor organoids: advances, applications, and future directions in biomedical research. [PDF]

Front Med (Lausanne)
Patient-derived tumor organoids (PDTOs) have become a key tool in cancer and translational oncology because they are physiologically relevant, 3D in vitro systems that preserve the genetic, epigenetic and phenotypic features of patient tumors. PDTOs generated from primary, metastatic surgical
Acar A.
europepmc   +5 more sources

Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids. [PDF]

Nucleic Acids Res, 2022
Abstract Patient-derived tumor organoids (PDOs) have emerged as a reliable in vitro model for drug discovery. However, RNA sequencing-based analysis of PDOs treated with drugs has not been realized in a high-throughput format due to the limited quantity of organoids. Here, we translated a newly developed pooled RNA-seq methodology onto a
Wu Y, Li K, Li Y, Sun T, Liu C, Dong C, Zhao T, Tang D, Chen X, Chen X, Liu P.   +10 more
europepmc   +5 more sources

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy [PDF]

Frontiers in Oncology, 2022
Cancer immunotherapy has revolutionized the field of cancer treatment in recent years. However, not all patients receiving cancer immunotherapy exhibit durable responses, and reliable, high-throughput testing platforms are urgently needed to guide ...
Ji Wang, Chao Chen, Chao Chen, Chao Chen, Lu Wang, Mingjun Xie, Mingjun Xie, Xinyang Ge, Sufan Wu, Yong He, Yong He, Yong He, Yong He, Xiaozhou Mou, Chenyang Ye, Chenyang Ye, Chenyang Ye, Yi Sun   +17 more
doaj   +2 more sources

Chinese experts consensus on quality control standards for tumor organoids diagnosis and treatment platform (2022 version) [PDF]

Zhongguo aizheng zazhi, 2022
Recently, advances in organoid technology have opened new avenues for the development of novel models of human cancer. Patient-derived tumor organoids retain phenotypes such as histopathological, genetic and molecular features of the original tumor.
The Society of Cancer Multidisciplinary Diagnosis and Treatment, China Anti-Cancer Association, The Society of Cancer Endocrinology, China Anti-Cancer Association
doaj   +3 more sources

Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities

STAR Protocols, 2022
Summary: Patient-derived tumor organoids can be predictive of patient’s treatment responses, and normal tissue-derived organoids allow for drug toxicity testing.
Camilla Calandrini, Jarno Drost
doaj   +1 more source